T-cell receptor therapy shows early anti-tumor activity in phase I study

New biomarker can predict cancer aggressiveness, study finds

Researchers from Fred Hutch Cancer Center and the University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers using a new technology and computational method.

February 21, 2025

Vol.51 No.07

Clinical Roundup

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

A phase II trial found that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy. Exploratory analysis suggests greater HER2 amplification in a tumor may be associated with greater clinical benefit of dual HER2 inhibitor vs EGFR inhibitor therapy.

January 31, 2025

Vol.51 No.04

Clinical Roundup

Epigenetic research reveals a potential treatment for CRC and other solid tumors

A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells and potentially could be used to treat solid tumors, according to a new study from researchers at the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences.

January 17, 2025

Vol.51 No.02

In Brief

MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award

Lauren Averett Byers, professor of thoracic/head & neck medical oncology at the University of Texas MD Anderson Cancer Center, received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology. The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer, which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.

December 13, 2024

Vol.50 No.46

Clinical Roundup

CAR T cells armed with IL-15 show promise in treating solid cancers

A study published in the journal Nature reports results of the first-in-human phase I clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3. Researchers at Baylor College of Medicine and Texas Children’s Cancer Center led the study, which tested chimeric antigen receptor T cells enhanced with the protein interleukin-15.

December 06, 2024

Vol.50 No.45

Clinical Trials & Tribulations

Menin inhibitors emerge as new treatment for advanced AML

The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia.

November 22, 2024

Vol.50 No.44

By Ghayas Issa